Bio-Techne Corp at Barclays Global Healthcare Conference (Virtual) Transcript
Good morning, everybody. Welcome to Day 3 of our healthcare conference. Luke Sergott, I cover life science tools and diagnostics here at Barclays. I have the pleasure of Bio-Techne management team, Chuck Kummeth; Jim Hippel; and et al with us. I think they're going to give a little overview, a couple of sentences or background, and we're just going to dive right in.
All right. David is going to run some slides here. It's always interesting to do these virtual. I never know if I'm talking to 5 people or 5,000, but we'll pretend it's 1,000. Okay. So this is Bio-Techne, a 43-year-old company now. Here is our usual disclaimer. We won't waste any time on this. Everybody knows what this here is about. Move on.
So what are we about? So we recently touched $16 billion, but roughly $14 billion of a market cap company now. We're a fiscal company. So as of last June, we were $739, we're blowing that number out
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
